Ministry of Health

Assistive Devices Program 5700 Yonge Street, 7th Floor Toronto ON M2M 4K5

www.health.gov.on.ca/adp

Tel.: 416-327-8804 Fax.: 416-327-8192 Toll Free: 1-800-268-6021 TTY: 416-327-4282 1-800-387-5559 TTY: E-mail: adp@ontario.ca

Ministère de la Santé

Programme d'appareils et accessoires fonctionnels

5700, rue Yonge, 7e étage Toronto (ON) M2M 4K5 www.health.gov.on.ca/paaf

Tél. : 416-327-8804 Téléc.: 416-327-8192 Sans frais: 1-800-268-6021 **ATS**: 416-327-4282 1-800-387-5559 ATS: Courriel: adp@ontario.ca



Memorandum

To: ADP-Registered Vendors of Respiratory Equipment and Supplies

From: Eva Roszuk, Director, Assistive Devices Program

Date: February 10, 2020

Subject: New Pricing Schedule for Positive Airway Pressure (PAP) Systems

The Ministry of Health conducted a review of the Assistive Devices Program (ADP) approved prices for positive airway pressure (PAP) systems in response to the recommendations in the 2018 Annual Report from the Office of the Auditor General of Ontario.

In order to make PAP systems more affordable for Ontarians, the government is implementing a price change for these devices, which will result in lower co-payment costs for patients, starting April 1, 2020.

The ADP Approved Prices will decrease for the following device categories, effective April 1, 2020:

- Continuous positive airway pressure (CPAP) systems price will decrease from \$860 to \$554, resulting in a \$77 decrease in a client's co-payment;
- Auto-titrating positive airway pressure (APAP) systems price will decrease from \$1020 to \$554, resulting in a \$117 decrease in a client's co-payment; and,
- Bi-level positive airway pressure (BPAP) systems price will decrease from \$1120 to \$950, resulting in a \$43 decrease in a client's co-payment.

Price changes were informed by extensive market and trend analysis, other jurisdictions, targeted margin analysis, expert advice, and the size of Ontario and its program.

The ADP has also eliminated the additional medical eligibility criteria for APAP systems. As of April 1, 2020, to receive funding for an APAP system, the applicant must only demonstrate a diagnosis of Obstructive Sleep Apnea Syndrome and the presence of significant symptoms or medical risks without treatment, and the absence of symptoms or risks with treatment.

There are no changes to ADP policies related to ADP-registered vendor's role and responsibilities.

The government values your contribution to our public health care system and your ongoing efforts to meet the needs of the ADP patients and will continue to work with you to manage this transition.

All questions related to this memorandum should be sent to adpvendors@ontario.ca.

(original signed by)

Eva Roszuk Director Assistive Devices Program